DPP-4 inhibitors are less effective than metformin for reducing hemoglobin A1c | ACP Diabetes Monthly
A meta-analysis of randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to metformin and other drugs found that DPP-4 monotherapy is less effective.
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization | ACP Diabetes Monthly
If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
Intensive weight management in primary care improved weight loss and remission of type 2 diabetes | ACP Diabetes Monthly
The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to
Review compares effectiveness, cost, and safety of second-line drugs for diabetes | ACP Diabetes Monthly
The review found that sulfonylureas were more cost-effective than newer agents, but an ACP Journal Club commentary stressed the importance of shared decision making in the choice of a second agent.
Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections | ACP Diabetes Monthly
The authors of an accompanying ACP Journal Club commentary noted that although the risk for bias in the five reviewed studies was reportedly low, the results were imprecise and inconsistent, leaving little confidence in the evidence of an apparent
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years | ACP Diabetes Monthly
The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM | ACP Diabetes Monthly
A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.
In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER | ACP Diabetes Monthly
Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
The results are in accordance with guidelines and regulatory policy recommendations that have extended use of metformin to individuals with mild to moderate kidney impairment, an ACP Journal Club commentary said.
In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events | ACP Diabetes Monthly
The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.